Major complications as a result of MWA are rare and tolerable.[25–28] Therefore, we performed the retrospective multicenter study to explore the potential benefit of MWA in treating EGFR acquired resistance NSCLC with extra-CNS oligoprogressive disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.